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America). These measures would also reduce the risk of 
introducing new strains of P. destructans to regions where 
bats are already infected (e.g., eastern North America and 
Europe). These measures are necessary to prevent the 
devastating effects this pathogen has had on bats in North 
America and would help maintain the ecosystem services 
that bats provide (9,10).
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To the Editor: In 2009, 2010, and 2013, Neisseria 
gonorrhoeae strains H041 (ceftriaxone MIC of 2 mg/L), 
F89 (ceftriaxone MIC of 1 mg/L), and A8806 (ceftriax-
one MIC of 0.5 mg/L) were isolated from samples from 
patients in Japan (1), France (2) and Australia (3), respec-
tively. In Japan, no other clinical N. gonorrhoeae strains 
with decreased susceptibility to ceftriaxone were reported 
until 2014, when clinical strain GU140106 (ceftriaxone 
MIC of 0.5 mg/L) was isolated from a man in in Nagoya, 
Japan. We report details of this case and sequencing results 
of the penA gene for the strain. The study was approved by 
the Institutional Review Board of the Graduate School of 
Medicine, Gifu University, Japan.
N. gonorrhoeae strain GU140106 was isolated from a 
urethral swab sample from a man with acute urethritis. The 
man had received fellatio, without condom use, from a fe-
male sex worker in Nagoya in December 2013. He visited 
our clinic in January 2014 for urethral discharge. Culture 
of a urethral swab sample was positive for N. gonorrhoeae. 
We used the Cobas 4800 CT/NG Test (Roche Molecular 
Systems Inc., Pleasanton, CA, USA) to test a first-voided 
urine sample; results were positive for N. gonorrhoeae but 
negative for Chlamydia trachomatis. The infection was 
treated with a single-dose regimen of ceftriaxone (1 g) ad-




the man reported no symptoms, and his first-voided urine 
sample was negative for leukocytes. The test-of-cure for N. 
gonorrhoeae was not performed. The female sex worker 
could not be examined for the presence of N. gonorrhoeae 
strain GU140106 in her pharynx.
The strain was confirmed to be a gonococcal species 
by testing with Gonochek-II (TCS Biosciences Ltd, Buck-
ingham, UK), the HN-20 Rapid system identification test 
(Nissui, Tokyo, Japan), and the Aptima Combo 2 assay 
for CT/NG (Hologic, Inc., Bedford, MA, USA) and by 
16S rRNA gene sequencing and porA pseudogene PCR 
(4). MICs of antimicrobial drugs for GU140106 were as 
follows, as determined by using the agar dilution method: 
2.0 mg/L for penicillin G, 1.0 mg/L for tetracycline, 2.0 
mg/L for cefixime, 0.5 mg/L for ceftriaxone, 8.0 mg/L for 
levofloxacin, 0.5 mg/L for azithromycin, and 32.0 mg/L 
spectinomycin. The strain was determined to be resistant to 
penicillin G, tetracycline, cefixime, ceftriaxone, and levo-
floxacin, according to criteria of the European Committee 
on Antimicrobial Susceptibility Testing (5).
The penA gene of strain GU140106 was sequenced as 
previously described (6); results showed the presence of a 
novel mosaic penicillin-binding protein 2 (PBP2; GenBank 
accession no. LC056026) (Figure). Multilocus sequence 
typing (MLST) and N. gonorrhoeae multiantigen sequence 
typing (NG-MAST) of GU140106 were performed as pre-
viously reported (8,9). MLST assigned strain GU140106 to 
sequence type 7363, the same as strains H041 and A8806 
(1,2). NG-MAST assigned strain GU140106 to sequence 
type 6543. MLST and NG-MAST results for GU140106 
differed from those for F89 (3).
Since the naming of the mosaic PBP2 associated with 
decreased susceptibilities to oral cephalosporins as pattern 
X (6), various PBP2 mosaic structures have been discov-
ered. Mosaic PBP2 structures are basically composed of 
fragments analogous to PBP2s in Neisseria species. Before 
strain H041 emerged, strains harboring mosaic PBP2s had 
been resistant to oral cephalosporins but susceptible to cef-
triaxone. H041 (ceftriaxone MIC of 2 mg/L) had additional 
novel amino acid changes, including A311V, V316P, and 
T483S, in its mosaic PBP2. The presence of substitutions 
A311V, V316P, and T483S was reported to be responsible 
for resistance to ceftriaxone (7). Like strain H041, strains 
GU140106 and A8806 (ceftriaxone MICs of 0.5 mg/L) 
had substitutions A311V and T483S, but instead of sub-
stitution V316P, they had substitution V316T. In addition, 
GU140106 had several changes in positions 227–281 that 
were not present in other strains. These alterations might 
also contribute to the decreased susceptibility to ceftriaxone.
On the basis of pharmacodynamic analyses (10), a 1-g 
dose of ceftriaxone (the recommended first-line treatment 
for gonorrhea in Japan) would be effective against genital 
gonorrhea caused by strains exhibiting decreased suscepti-
bility to ceftriaxone (e.g., strains GU140106 and A8806). 
However, such strains could be resistant to lower-dose regi-
mens, including 250-mg and 500-mg doses of ceftriaxone.
This N. gonorrhoeae strain, GU140106, was isolat-
















female sex worker; thus, the bacteria could have derived 
from her pharynx. N. gonorrhoeae strain H041 was previ-
ously isolated from the pharynx of a female sex worker (1). 
To prevent the emergence and spread of ceftriaxone-resistant 
N. gonorrhoeae, pharyngeal gonorrhea must be treated. It is 
uncertain whether a 1-g dose of ceftriaxone would be effec-
tive against pharyngeal gonorrhea caused by strains with 
decreased susceptibility to ceftriaxone, and this regimen 
might facilitate the selection of such strains from oral ceph-
alosporin-resistant strains in the pharynx. The emergence 
of N. gonorrhoeae GU140106 in Japan suggests that new 
strategies (not just increased ceftriaxone doses), including 
combination treatment with ceftriaxone and another class of 
antimicrobial drugs and multiple dose regimens of ceftriax-
one, might be required to treat pharyngeal gonorrhea.
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To the Editor: In 2005, the World Health Organiza-
tion (WHO) proposed to eliminate measles in the Western 
Pacific Region by 2012, and in 2006, China began a 6-year 
measles elimination campaign. The strategy included a 
routine 2-dose measles-containing vaccine (MCV) for chil-
dren 8 months and 18–23 months of age, supplemented by 
nationwide vaccination activities in 2010 for children born 
during 1996–2010 (1). As a result, China’s measles inci-
dence rate has dropped sharply since 2008 and reached its 
lowest level (0.46 cases/100,000 population) in 2012 (2). 
However, the rate has risen again since 2012; in 2014, in-
cidence was 3.88 cases/100,000 population (3). Shenyang, 
a hub city in northeastern China, experienced a massive 
measles outbreak in 2014, and we analyzed the causes and 
characteristics of this outbreak.
Shenyang Center of Disease Control reported 2,058 
confirmed measles cases (1,447 laboratory diagnosed, 611 
clinically diagnosed) in 2014 (25.02 cases/100,000 popula-
tion), much higher than that reported in Shenyang in 2013 
(2.33/100,000). Most cases occurred in children 0–1 years 
of age (487 cases; 1,145.77/100,000), followed by per-
sons 25–30 (227 cases; 28.57/100,000), 30–35 (203 cases; 
32.42/100,000), and 35–40 (203 cases; 35.02/100,000) 
years of age. Among all 2,058 confirmed cases, 438 pa-
tients were hospitalized because of measles complications; 
no deaths were reported.
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